Rodman & Renshaw Initiates Coverage On MannKind With Buy Rating, Announces Price Target of $8
Rodman & Renshaw Initiates Coverage On MannKind With Buy Rating, Announces Price Target of $8
羅德曼與仁信初始對曼恩凱德生物醫療給予買入評級，公佈目標價爲8美元。
Rodman & Renshaw analyst Brandon Folkes initiates coverage on MannKind (NASDAQ:MNKD) with a Buy rating and announces Price Target of $8.
Rodman＆Renshaw分析師Brandon Folkes開始對曼恩凱德生物醫療（NASDAQ:MNKD）進行買入評級，並宣佈目標價格爲8美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。